X4 Pharmaceuticals outlines expected 2026 Phase 3 trial data release for mavorixafor
Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...